Routine Versus Selective Protamine Administration to Reduce Bleeding Complications After Transcatheter Aortic Valve Implantation (POPular ACE TAVI)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1000 participants.

Also called NCT05774691

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 1,000 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05774691
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05774691. Randomized; triple masking; primary purpose prevention. Start 2023-11-01 (actual); primary completion 2026-01-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Routine Versus Selective Protamine Administration to Reduce Bleeding Complications After Transcatheter Aortic Valve Implantation (POPular ACE TAVI)
Condition
Aortic Valve Stenosis
Intervention (Drug)
Protamine sulfate
Intervention (Drug)
Protamine sulfate
Lead sponsor
St. Antonius Hospital (class: other)
Collaborator
St. Antonius Research Fund (class: not stated)

Record details

Record id
cardio:ct-nct05774691
Content hash
f344fe6194b00626a688c1d60ba470a17e3ca7bf0809475f6404f08f90071291